IP Library Granted Patent US 9,982,277
Granted Patent B2
US 9,982,277 · App. 14/897,026 · Granted May 29, 2018

Methods and compositions for target DNA modification

Inventors: Douglas E. Koshland (Berkeley, CA); Lamia Wahba (Berkeley, CA)
Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
C12N15/902C12N15/102C12N15/905
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,982,277
App. No.
14/897,026
Granted
May 29, 2018
Kind
B2
Abstract

The disclosure provides compositions and methods for increasing efficiency of Cas9-mediated target DNA modification. Specifically, the disclosure provides compositions and methods for carrying out site-directed modification of a target DNA, the methods comprising contacting the target DNA with: a) a complex comprising a Cas9 polypeptide and a guide RNA, and b) a Rad51 polypeptide. The site-directed modification of a target DNA can be carried out in a living cell in vitro, in a living cell in vivo, or in a cell-free system in vitro.

Claims (9)

1. A method for increasing the efficiency of site specific cleavage of a target DNA, the method comprising contacting the target DNA with:

a) a complex comprising a Cas9 polypeptide and a guide RNA, wherein the guide RNA comprises a first segment comprising a nucleotide sequence that is complementary to a sequence in the target DNA and a second segment that binds to the Cas9 polypeptide; and

b) an amount of a Rad51 polypeptide sufficient to enhance binding of the first segment to the target DNA.

2. The method of claim 1 , wherein the method is an in vitro method.

3. The method of claim 1 , wherein the method is an in vivo method and wherein the target DNA is comprised within a living cell.

4. The method of claim 3 , wherein the Rad51 polypeptide is heterologous to the cell.

5. The method of claim 3 , wherein the cell modified in the in vivo method has been genetically modified to comprise a heterologous nucleic acid that comprises a nucleotide coding sequence encoding the Rad51 polypeptide.

6. The method of claim 5 , wherein the nucleotide sequence is operably linked to a promoter that is functional in the cell.

7. The method of claim 5 , wherein said genetic modification provides for a level of Rad51 that is at least 10% higher than the level of Rad51 polypeptide in a control cell not genetically modified with a heterologous nucleic acid that comprises a nucleotide sequence encoding the Rad51 polypeptide.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2017
From: KOSHLAND, DOUGLAS E.; WAHBA, LAMIA
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 041529/0621 →
Continuity (2)
Provisional Application 61833798 · Jun 11, 2013
Related Publication 20160138045A1 · May 19, 2016